Amarin Corp Plc (AMRN)

[Whalatane]

alm2 while I agree with most of your post ...this section

Everything as to Amarins future hinges on this appeal outcome - although there would still remain some value in the company if the appeal is lost

So what value do you place on future EU business ...either as GIA , partnership or my preference ...out right sale of EU rights .
Since you're based in the UK ...maybe you could write a post some time and explain to the board the difference between the US and EU healthcare systems .

My understanding of EU health care is that every effort is made to cover everyone at some basic level. But tied with that is the requirement that drugs be cost effective for those they are prescribed too.
So when you look at the costs of PCI's in the major countries like the UK , Germany, France etc ....altho less than in the US ...it's still very cost effective to provide low cost coverage for all diabetic secondary prevention CAD patients ...and probably a lot more .

So there's a real market there ...those EU health systems will save money prescribing Vascepa to select patient groups ...regardless of what happens with the US appeal. .

Since there is a real market there ...what is AMRN's best way to exploit / develop that ....GIA, partnership , sale of EU rights ?...and why ?

thx
Kiwi